Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as vopimetostat
TNG462 vopimetostat · 1 trial · 1 indication
A DLT is defined as a treatment-emergent adverse event occurring during Cycle 1 that is considered at least possibly related to TNG462, lorlatinib, or the combination and is not clearly attributable to underlying disease, intercurrent illness, or concomitant medications. DLTs include Grade ≥3 non-hematologic toxicities with specified exceptions for transient or manageable events; clinically significant hepatic, pulmonary, pancreatic, cardiac, ECG, CNS, or neurocognitive toxicities; Grade 4 hematologic toxicities; Grade ≥3 febrile neutropenia; Grade ≥3 thrombocytopenia with clinically significant bleeding; prolonged treatment-related hematologic toxicity requiring interruption of both study drugs for \>14 consecutive days; any toxicity resulting in permanent discontinuation of both study drugs during Cycle 1 due to safety concerns; and any death at least possibly related to study treatment during the DLT assessment period.
The study uses a Backfill Bayesian Optimal Interval (BF-BOIN) design to determine the MTD of TNG462. TNG462 will start at 200 mg QD and may be escalated to 250 mg QD at the optional Dose Level 3 if Dose Level 2 is tolerated, at the discretion of the Sponsor-Investigator.
The study uses a BF-BOIN design to determine the MTD of Lorlatinib. Lorlatinib will start at 50 mg QD and may be escalated to 75 mg QD at Dose Level 2 if Dose Level 1 is tolerated. Lorlatinib will remain at 75 mg QD at the optional Dose Level 3.
The study uses a BF-BOIN design to determine the MTD. The RP2D is selected from among acceptable dose levels at or below the MTD based on the totality of safety, tolerability, pharmacokinetic, and preliminary antitumor activity data obtained during Phase I.
| Arm | Type | Description |
|---|---|---|
| TNG462 plus Lorlatinib | EXPERIMENTAL | Participants receive TNG462 once daily and lorlatinib once daily according to the study treatment plan and study calendar. |
| Name | Type | Description |
|---|---|---|
| TNG462 vopimetostat | DRUG | Investigational drug Supplier/manufacturer: Tango Therapeutics |
| Lorlatinib | DRUG | Source/manufacturer: Commercial supply / Pfizer |
Inclusion Criteria: * Age ≥ 18 years * Histologically or cytologically confirmed NSCLC harboring an ALK rearrangement, documented by an FDA/EMA-approved or validated local test. * Confirmed MTAP loss, demonstrated by immunohistochemistry (IHC) as complete loss in the presence of a positive internal...